EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) – Pipeline Insight, 2020
This report can be delivered to the clients within 72 - 96 Hours
DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Non-Small Cell Lung Cancer (NSCLC): Overview
Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.
The three main histological subtypes of Non-Small Cell Lung Cancer are:
An important part of the immune system is its ability to keep itself from attacking normal cells in the body. To do this, it uses “checkpoint” proteins on immune cells, which act like switches that need to be turned on (or off) to start an immune response. Cancer cells sometimes use these checkpoints to avoid being attacked by the immune system. Drugs that target these checkpoints (called checkpoint inhibitors) can be used to treat some people with non-small cell lung cancer (NSCLC). Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer.
Epidermal growth factor receptor (EGFR)
Epidermal growth factor receptor is a trans-membrane glycoprotein with an extracellular epidermal growth factor binding domain and an intracellular tyrosine kinase domain that regulates signaling pathways to control cellular proliferation. Epidermal growth factor receptor binding to its ligand results in autophosphorylation by intrinsic tyrosine/kinase activity, triggering several signal transduction cascades. Constitutive or sustained activation of these sequences of downstream targets is thought to yield more aggressive tumor phenotypes. Mutations in epidermal growth factor receptor have been discovered in association with some lung cancers.
EGFR function and its role in lung cancer
EGFR belongs to the erbB family of closely related receptor tyrosine kinases, which include erbB1 (also known as EGFR), erbB2 (HER2), erbB3, and erbB4. Although their basic structures are similar, each one has distinct properties, including variation in tyrosine kinase activity. It has an extracellular ligand binding domain, a transmembrane portion, and intracellular tyrosine kinase and regulatory domains. Upon binding of a specific ligand (eg. epidermal growth factor), the normally functioning EGFR undergoes conformational change and phosphorylation of the intracellular domain occurs, leading to downstream signal transduction by various pathways. These include the Raf1-extracellular signal-regulated kinase, PI3K/Akt, and signal transducer and activator of transcription (STAT) factors. Depending on the pathway, the end result is cell proliferation or cell maintenance by inhibition of apoptosis.
EGFR inhibitors
Epidermal growth factor receptor (EGFR) is a protein on the surface of cells. It normally helps the cells grow and divide. Some Non-Small Cell Lung Cancer cells have too much EGFR, which makes them grow faster. Drugs called EGFR inhibitors can block the signal from EGFR that tells the cells to grow. Some of these drugs can be used to treat advanced Non-Small Cell Lung Cancer.
EGFR inhibitors used in Non-Small Cell Lung Cancer with EGFR gene mutations
EGFR Non-Small Cell Lung Cancer Emerging Drugs Chapters
This segment of the EGFR Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
EGFR Non-Small Cell Lung Cancer Emerging Drugs
Novartis is conducting a phase I/II, multicenter, open-label study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFRmut solid malignancies. This study will estimate the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (Phase l part) of EGF816 and to investigate the anti-tumor activity of EGF816 (Phase II part).
Further product details are provided in the report……..
EGFR Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different EGFR Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
EGFR Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses EGFR Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging EGFR Non-Small Cell Lung Cancer drugs.
Report Highlights
EGFR Non-Small Cell Lung Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Non-Small Cell Lung Cancer (NSCLC): Overview
Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.
The three main histological subtypes of Non-Small Cell Lung Cancer are:
- Adenocarcinoma: About 40% of all lung cancers are adenocarcinomas. These tumors start in mucus-producing cells that line the airways.
- Squamous cell carcinoma (SCC): About 25-30% of all lung cancers are Squamous cell carcinoma. This type of cancer develops in cells that line the airways and is usually caused by smoking.
- Large cell (undifferentiated) carcinoma: This type makes up around 10-15% of all lung cancers. It gets its name from the way that the cancer cells look when they are examined under a microscope.
An important part of the immune system is its ability to keep itself from attacking normal cells in the body. To do this, it uses “checkpoint” proteins on immune cells, which act like switches that need to be turned on (or off) to start an immune response. Cancer cells sometimes use these checkpoints to avoid being attacked by the immune system. Drugs that target these checkpoints (called checkpoint inhibitors) can be used to treat some people with non-small cell lung cancer (NSCLC). Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer.
Epidermal growth factor receptor (EGFR)
Epidermal growth factor receptor is a trans-membrane glycoprotein with an extracellular epidermal growth factor binding domain and an intracellular tyrosine kinase domain that regulates signaling pathways to control cellular proliferation. Epidermal growth factor receptor binding to its ligand results in autophosphorylation by intrinsic tyrosine/kinase activity, triggering several signal transduction cascades. Constitutive or sustained activation of these sequences of downstream targets is thought to yield more aggressive tumor phenotypes. Mutations in epidermal growth factor receptor have been discovered in association with some lung cancers.
EGFR function and its role in lung cancer
EGFR belongs to the erbB family of closely related receptor tyrosine kinases, which include erbB1 (also known as EGFR), erbB2 (HER2), erbB3, and erbB4. Although their basic structures are similar, each one has distinct properties, including variation in tyrosine kinase activity. It has an extracellular ligand binding domain, a transmembrane portion, and intracellular tyrosine kinase and regulatory domains. Upon binding of a specific ligand (eg. epidermal growth factor), the normally functioning EGFR undergoes conformational change and phosphorylation of the intracellular domain occurs, leading to downstream signal transduction by various pathways. These include the Raf1-extracellular signal-regulated kinase, PI3K/Akt, and signal transducer and activator of transcription (STAT) factors. Depending on the pathway, the end result is cell proliferation or cell maintenance by inhibition of apoptosis.
EGFR inhibitors
Epidermal growth factor receptor (EGFR) is a protein on the surface of cells. It normally helps the cells grow and divide. Some Non-Small Cell Lung Cancer cells have too much EGFR, which makes them grow faster. Drugs called EGFR inhibitors can block the signal from EGFR that tells the cells to grow. Some of these drugs can be used to treat advanced Non-Small Cell Lung Cancer.
EGFR inhibitors used in Non-Small Cell Lung Cancer with EGFR gene mutations
- Erlotinib (Tarceva)
- Afatinib (Gilotrif)
- Gefitinib (Iressa)
- Osimertinib (Tagrisso)
- Dacomitinib (Vizimpro)
EGFR Non-Small Cell Lung Cancer Emerging Drugs Chapters
This segment of the EGFR Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
EGFR Non-Small Cell Lung Cancer Emerging Drugs
- DZD9008: Dizal Pharmaceuticals
- Nazartinib (EGF816) - Novartis Pharmaceuticals
Novartis is conducting a phase I/II, multicenter, open-label study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFRmut solid malignancies. This study will estimate the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (Phase l part) of EGF816 and to investigate the anti-tumor activity of EGF816 (Phase II part).
Further product details are provided in the report……..
EGFR Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different EGFR Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in EGFR Non-Small Cell Lung Cancer
Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intramuscular
- Oral
- Intratumoral
- Intravenous
- Molecule Type
- Gene therapies
- Bispecific antibodies
- Immunotherapies
- Monoclonal antibodies
- Small molecules
- Product Type
EGFR Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses EGFR Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging EGFR Non-Small Cell Lung Cancer drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence EGFR Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve EGFR Non-Small Cell Lung Cancer.
- July 2020: FDA grants Breakthrough Therapy designation to osimertinib for early-stage EGFR+ NSCLC
- Real-World Study Expands Benefit-Risk Assessment Data for osimertinib in EGFR+ NSCLC
EGFR Non-Small Cell Lung Cancer Report Insights
- EGFR Non-Small Cell Lung Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing EGFR Non-Small Cell Lung Cancer drugs?
- How many EGFR Non-Small Cell Lung Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of EGFR Non-Small Cell Lung Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the EGFR Non-Small Cell Lung Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for EGFR Non-Small Cell Lung Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Dizal Pharmaceuticals
- Novartis Pharmaceuticals
- AstraZeneca
- Betta Pharmaceuticals Co., Ltd.
- Hangzhou ACEA Pharmaceutical Research
- G1 Therapeutics, Inc.
- Millennium Pharmaceuticals, Inc.
- Takeda
- Janssen Research & Development, LLC
- Sinocelltech Ltd.
- Allist Pharmaceuticals, Inc.
- DZD9008
- EGF816
- AZD3759
- Icotinib
- AC0010
- BPI-7711
- TAK-788
- JNJ-61186372
- SCT200
Introduction
Executive Summary
EGFR Non-Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
EGFR Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
EGFR Non-Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
EGFR Non-Small Cell Lung Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Mobocertinib (TAK 788): ARIAD Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
AZD3759: AstraZeneca
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I/II)
Comparative Analysis
DZD9008: Dizal Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
EGFRm inhibitors: HitGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
EGFR Non-Small Cell Lung Cancer Key Companies
EGFR Non-Small Cell Lung Cancer Key Products
EGFR Non-Small Cell Lung Cancer- Unmet Needs
EGFR Non-Small Cell Lung Cancer- Market Drivers and Barriers
EGFR Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
EGFR Non-Small Cell Lung Cancer Analyst Views
EGFR Non-Small Cell Lung Cancer Key Companies
Appendix
Executive Summary
EGFR Non-Small Cell Lung Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
EGFR Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
EGFR Non-Small Cell Lung Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
EGFR Non-Small Cell Lung Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Mobocertinib (TAK 788): ARIAD Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
AZD3759: AstraZeneca
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I/II)
Comparative Analysis
DZD9008: Dizal Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
EGFRm inhibitors: HitGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
EGFR Non-Small Cell Lung Cancer Key Companies
EGFR Non-Small Cell Lung Cancer Key Products
EGFR Non-Small Cell Lung Cancer- Unmet Needs
EGFR Non-Small Cell Lung Cancer- Market Drivers and Barriers
EGFR Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
EGFR Non-Small Cell Lung Cancer Analyst Views
EGFR Non-Small Cell Lung Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for EGFR Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for EGFR Non-Small Cell Lung Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for EGFR Non-Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for EGFR Non-Small Cell Lung Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products